These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 328135)

  • 21. [The theory and practice of chemotherapy by arterial infusion--the importance of pharmacokinetic research].
    Taguchi T
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1717-28. PubMed ID: 6383219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based pharmacokinetic models for anticancer drugs.
    Chen HS; Gross JF
    Cancer Chemother Pharmacol; 1979; 2(2):85-94. PubMed ID: 93986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations.
    Chuang S
    Cancer Chemother Rep; 1975; 59(4):827-42. PubMed ID: 1175173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of the route of administration on the relative effectiveness of 3',5'-dichloroamethopterin and amethopterin against advanced leukemia (L1210) in mice.
    VENDITTI JM; SCHRECKER AW; MEAD JA; KLINE I; GOLDIN A
    Cancer Res; 1960 Nov; 20():1451-6. PubMed ID: 13780697
    [No Abstract]   [Full Text] [Related]  

  • 27. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
    Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
    Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to Pediococcus cerevisiae to amethopterin as a consequence of changes in enzymatic activity and cell permeability. II. Permeability changes to amethopterin and other folates in the drug-resistant mutant.
    Mandelbaum-Shavit F
    Biochim Biophys Acta; 1976 May; 428(3):674-82. PubMed ID: 6055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical pharmacology of lipophilic diaminopyrimidine antifolates in mouse and human cells in vitro.
    Greco WR; Hakala MT
    Mol Pharmacol; 1980 Nov; 18(3):521-8. PubMed ID: 6970329
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies concerned with overcoming resistance to methotrexate: a comparison of the effects of methotrexate and 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (BW50197) on the colony forming ability of L5178Y cells.
    Hill BT; Goldie JH; Price LA
    Br J Cancer; 1973 Sep; 28(3):263-8. PubMed ID: 4743908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
    Chen G; Wright JE; Rosowsky A
    Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deaza aalogues of amethopterin (methotrexate).
    Montgomery JA; Elliott RD; Straight SL; Temple C
    Ann N Y Acad Sci; 1971 Nov; 186():227-34. PubMed ID: 5002299
    [No Abstract]   [Full Text] [Related]  

  • 34. Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bertino JR
    Cancer Res; 1979 Feb; 39(2 Pt 1):293-304. PubMed ID: 310709
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paradoxical effect of BW 301U, a lipophilic antifolate, on methotrexate-inhibitable deoxyuridine incorporation by human hematopoietic cells.
    Iland HJ; Laszlo J; Sedwick WD
    Cancer Res; 1985 Aug; 45(8):3962-8. PubMed ID: 3860291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The folate receptor as a rational therapeutic target for personalized cancer treatment.
    Assaraf YG; Leamon CP; Reddy JA
    Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
    Serano RD; Sigel CW; Nichol CA; Bigner DD
    Cancer Treat Rep; 1982 Jan; 66(1):99-106. PubMed ID: 6272992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic index of cytotoxic chemotherapy depends upon circadian drug timing.
    Von Roemeling R
    Ann N Y Acad Sci; 1991; 618():292-311. PubMed ID: 2006791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of dihydrofolate reductase and cell growth by antifolates in a methotrexate-resistant cell line.
    Hamrell MR
    Oncology; 1984; 41(5):343-8. PubMed ID: 6540852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.